This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Shaping the Future of Myeloma Treatment

Shaping the Future of Myeloma Treatment

Format

Expert Perspective

Time to Complete

45 minutes

Released

July 11, 2019

Expires

July 11, 2020
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

Commercial Supporter

Support for this activity has been provided through educational grants from AbbVie Inc., Celgene Corporation, and Takeda Oncology.

Program Description

To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment plans, based on genomics and risk stratification, to achieve durable remission while minimizing toxicity.

Intended Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate the most current imaging procedures, cytogenetics, genomics, and other testing tools to define patient prognosis and risk stratification
  • Evaluate emerging data from clinical trials on treatment regimens for newly diagnosed patients to achieve the deepest and most durable response while balancing the risks for toxicities, taking patient factors into consideration
  • Evaluate emerging data from clinical trials on oral small-molecule-inhibitor– and immune-oncology–based treatment regimens
  • Evaluate emerging data from clinical trials on treatment regimens for patients who have relapsed from, or are refractory to, their treatment

Conflict Of Interest Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Faculty

Ivan M. Borrello, MD
Associate Professor of Oncology
Johns Hopkins University
Baltimore, Maryland

Dr. Borrello has disclosed the following relevant financial relationships:
Consultant, Advisor: Bristol-Myers Squibb, Celgene Corporation, WindMIL Therapeutics
Royalties, Patents: WindMIL Therapeutics
Stock Ownership: WindMIL Therapeutics

Sergio A. Giralt, MD
Chief Attending, BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Giralt has disclosed the following relevant financial relationships:
Advisory Board: Actinium Pharmaceuticals, Amgen, Celgene Corporation, Jazz Pharmaceuticals, Johnson & Johnson, Kite, Novartis, Spectrum Pharmaceuticals, Takeda
Research Funding: Actinium Pharmaceuticals, Amgen, Celgene Corporation, Johnson & Johnson, Miltenyi Biotec, Takeda

Joshua R. Richter, MD
Assistant Professor of Medicine
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Richter has disclosed the following relevant financial relationships:
Advisory Board: Adaptive Biotechnologies, Bristol-Myers Squibb, Janssen, Oncopeptides
Consultant, Advisor: Amgen, Celgene Corporation, Sanofi, Takeda
Speakers Bureau: Celgene Corporation, Janssen, Karyopharm, Takeda

Accredited Provider Disclosures

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation
Mary DeRome
, Director of Medical Communications and Education, has disclosed no relevant financial relationships.

RedMedEd
Denise C. LaTemple, PhD
, Director of Scientific Services, has disclosed no relevant financial relationships.
Heather Rafa, Program Manager, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, AbbVie Inc., Celgene Corporation, and Takeda Oncology do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, Multiple Myeloma Research Foundation, AbbVie Inc., Celgene Corporation, or Takeda Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For questions regarding CME credit, please contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference course code #G6472-20-T.

For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or education@redmeded.com.

Privacy Policy

CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Penn State College of Medicine may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine. For more information, contact ContinuingEd@hmc.psu.edu.

myCME privacy policy

Copyright

© 2019. This CME-certified program is held as copyrighted by Penn State College of Medicine and RedMedEd. Through this notice, Penn State College of Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue